ANAC Key Stats
|Revenue (Quarterly YoY Growth)||46.02%|
|EPS Diluted (TTM)||-1.550|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-58.46M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-465.5%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Anacor Pharmaceuticals: The Run Can Continue 12:07 PM
- Short Interest Makes 10.5% Move For ANAC The Street Dec 11
- ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Dec 10
- Nasdaq stocks posting largest percentage increases Dec 6
- Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 5.7% - Tale of the Tape Zacks Dec 6
- Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 5.7% Dec 6
- Nasdaq stocks posting largest percentage increases Dec 2
- Insider Buying Report: NLY, ANAC Forbes Dec 2
- 5 Stocks Poised for Breakouts The Street Dec 2
- Top Insider Trades: AGYS, ANAC, P, GMZ The Street Nov 28
ANAC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Anacor Pharmaceuticals is up 220.5% over the last year vs S&P 500 Total Return up 27.09%, Valeant Pharmaceuticals up 79.40%, and Actelion up 55.66%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ANAC
Pro Report PDF for ANAC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ANAC Pro Report PDF
Pro Strategies Featuring ANAC
Did Anacor Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Anacor Pharmaceuticals, Inc. is engaged in the discovery, development and commercialization of novel small molecule therapeutics derived from its novel boron chemistry platform.